Clinical Trial Update: Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma [Phase 1]

View source ↗

Summary

A Phase 1 safety study evaluating cabozantinib (XL184) in combination with temozolomide and radiation for newly diagnosed glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Glioblastoma, Giant Cell Glioblastoma | Phase 1 | Status: COMPLETED